INNOVADERM CRO IS NOW INDERO.

Join Us at AAD 2026 in Denver, Booth #3945!

Indero

Indero

Team of Experts

Author picture

We’re thrilled to announce that we’ll be exhibiting once again at the American Academy of Dermatology (AAD) Annual Meeting 2026, taking place in Denver, Colorado from March 27–31, 2026!

📍 Find us at Booth #3945

Connect with our team of leading dermatology experts and discover the latest innovations we’re introducing to the field. Whether you’re looking to explore new solutions, discuss clinical insights, or build strategic partnerships, this is the perfect opportunity to connect.

🎯 Book Your Meeting Now

Our calendar is filling up fast! Secure your one-on-one session with our dermatology specialists to ensure personalized time during the event.

👉 Don’t miss your chance to meet with our dermatology experts, schedule your meeting early!

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.